EP3768079A1 - Poulet transgénique qui produit des anticorps humains - Google Patents

Poulet transgénique qui produit des anticorps humains

Info

Publication number
EP3768079A1
EP3768079A1 EP19770329.1A EP19770329A EP3768079A1 EP 3768079 A1 EP3768079 A1 EP 3768079A1 EP 19770329 A EP19770329 A EP 19770329A EP 3768079 A1 EP3768079 A1 EP 3768079A1
Authority
EP
European Patent Office
Prior art keywords
chicken
human
sequences
synvh
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19770329.1A
Other languages
German (de)
English (en)
Other versions
EP3768079A4 (fr
Inventor
Philip A. Leighton
William Don Harriman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crystal Bioscience Inc
Original Assignee
Crystal Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crystal Bioscience Inc filed Critical Crystal Bioscience Inc
Publication of EP3768079A1 publication Critical patent/EP3768079A1/fr
Publication of EP3768079A4 publication Critical patent/EP3768079A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/30—Bird
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]

Definitions

  • a critical checkpoint in B cell development in chickens is in-frame V(D)J rearrangement, leading to expression of a functional B cell receptor complex at the cell surface (1-3).
  • the process of rearrangement in chickens utilizes the same recombination signal sequences and enzymes as in mammals, recombining V, D and J genes into functional V regions (4-8).
  • the main difference in chickens is that in both the light and heavy chain loci, there is only a single germline V gene and a single germline J gene, and in the heavy chain, a cluster of highly similar D segments (5,8), rather than the large number of diverse V, D and J genes in humans. The rearrangement process thus produces very little sequence diversity in the initial B cell repertoire.
  • Imperfect joins and exonucleolytic chewing back in the V-J and V-D-J junctions can generate some diversity, but chicken B cells do not express TdT (9), so there are no N-additions in CDR-H3 and in general, the immunoglobulin diversity produced by the gene rearrangement process is minimal (5,10,11).
  • chickens employ a process of gene conversion in which upstream pseudogenes in the light and heavy chain loci serve as sequence donors to mutate the expressed, functional V (8,11-13). These pseudogenes do not contain promoters or recombination signal sequences, so they cannot be expressed themselves, but their sequences are incorporated in segments of varying length into the single functional V.
  • rearrangement may be more related to providing intra-CDR-H3 disulfide bridges for stabilization of antigen-binding loops (17), since most Ds encode a single cysteine residue and D-D joins would thus encode paired cysteines. Diversity in chicken CDR-H3s comes from gene conversion/somatic hypermutation, rather than the rearrangement process itself.
  • This disclosure provides a transgenic chicken that produces human antibodies.
  • This disclosure provides, among other things, a transgenic chicken that has a modified immunoglobulin heavy chain immunoglobulin locus.
  • the modified locus has no endogenous V-D-J region and, instead, has a human VH segment, a human D cluster, a human J segment and a plurality of upstream pseudogenes based on human V H sequences.
  • the modified IgH locus undergoes V(D)J recombination in the chicken, gene conversion between the upstream pseudogenes and the human VH segment occurs, and the chicken produces antibodies that have a diversified immunoglobulin heavy chain, include CDR3s of differing lengths.
  • the present transgenic chicken may have certain advantages over other transgenic chickens that are designed to produce recombinant antibodies.
  • the IgH locus of the present transgenic chicken lacks the endogenous V-D-J region, thereby preventing the human sequences from being removed during V(D)J recombination (by, e.g., recombination between a chicken D and a human J).
  • the V-D-J region contains genes that are essential for fertility (i.e., the adam6a and adam6b genes, see, e.g., Marcello et al J. Biol. Chem. 2011 286: 13060-70 as well as US8,697,940).
  • the complete sequence of the endogenous V-D-J region in the chicken genome is currently unknown. As such, it was not clear whether the endogenous V-D-J region in the chicken genome contains essential genes, or a chicken that contains an IgH locus that lacks the entire contiguous endogenous chicken V-D-J region could be made. Further, the transgenic chicken produces antibodies that have a diversified immunoglobulin heavy chain, where the combination of V(D)J recombination, gene conversion, and somatic hypermutation contribute to the diversification.
  • CDR-H3s are produced by tandem D-D joining, and also probably by gene conversion, which can be used to insert sequences, delete sequences as well as just change sequences. Thus, even without terminal transferase, the CDR-H3s can still be long.
  • FIG. 1 provides diagrams of pre-rearranged and rearranging human VH segments in the chicken.
  • Top line, the SynVH-C transgene consists of a pre-rearranged human V region (hVDJ) with an upstream array of human pseudogenes.
  • the human V region splices to the downstream chicken constant regions (only Cmu is shown).
  • the chicken germline V and D genes, and pseudogene array, are upstream of the human V genes.
  • Upstream of the human germline V gene is an array of human-based pseudogenes. The upstream chicken germline V and D genes are deleted, but the chicken pseudogenes are still present.
  • FIG. 2 A-B provides a diagram of signal peptide changes observed in transgenic chickens and an alignment of germline signal peptide sequences.
  • the SynVH-SD signal peptide is less hydrophobic than that of SynVH-C and undergoes changes to become more hydrophobic.
  • the signal peptide can be changed to chicken sequences either by splicing of the chicken signal peptide exon to the human V region exon, or from gene conversion of the portion in the V region exon.
  • Human signal peptide is shown in yellow, chicken in orange.
  • the average hydrophobicity (Kyte-Doolittle, without normalization) is shown for each type of signal peptide.
  • the lysine residue that is often mutated to a hydrophobic residue in SynVH- SD is boxed.
  • the average hydrophobicity is indicated at right.
  • FIG. 3 provides CDR-H3 lengths.
  • CDR-H3 lengths show a broader distribution in SynVH-SD.
  • FIG. 4 provides SynVH-C and SynVH-SD amino acid frequencies.
  • SynVH-C and SynVH-SD amino acid frequencies in CDR-H3 are similar for most amino acids.
  • FIG. 5 depicts sequence diversity in CDR-H3 in SynVH-C and SynVH-SD.
  • Sequence diversity in CDR-H3 is similar in SynVH-C and SynVH-SD. Shannon entropy and amino acid distribution for each position of CDR-H3 IMGT positions 105-117 are shown for the specific lengths of 12 residues (top two panels) and 15 residues (bottom two panels) for SynVH-C and SynVH-SD. The sequences were drawn from the top 1000 sequences from each bird; SynVH-C, 6 birds, SynVH-SD, 3 birds.
  • FIG. 6 depicts hydrophobicity of CDR-H3 in synVH-C and SynVH-SD.
  • Hydrophobicity of CDR-H3 is similar in SynVH-C and SynVH-SD. Average hydrophobicity based on the normalized Kyte-Doolittle scale (34,35) of CDR-H3s of lengths 12-15 residues (IMGT positions 105-117) were calculated for the top 1000 sequences from each bird. The frequencies of each hydrophobicity value (grouped into increments of 0.1) are shown in the graphs.
  • FIG. 7 depicts the frequency of mAh sequences in NGS data.
  • the frequency of mAh sequences in NGS data show that many mAbs identified by GEM screening are rare in the spleen population. Number of times each antigen- specific mAh sequence identified in GEM screens was found in all of the sequencing data from each bird.
  • the mAbs are grouped by bird and transgene, either SynVH-C or SynVH-SD, as indicated. The number of mAbs from each bird is indicated below the plots. mAbs that were sequenced 5 or fewer times in the whole data set are colored red, showing that rare mAbs are found in the GEM screens.
  • FIG. 8 depicts alignments of human designed pseudogenes with the functional V sequences in each construct.
  • SynVH-C diverse CDR-H1, 2 and 3 sequences were obtained from the NIH EST database queried with the human VH3-23 gene.
  • the germline VH3-23 framework sequence was included in some of the pseudogenes, whereas others match the functional VH sequence (HuVH, top line) which is a somatically-derived sequence with 9 changes relative to the germline.
  • CDR-H1 and 2 were derived from the human VH3 family members, and place on the VH3-23 framework scaffold. No specific CDR-H3 sequences were included; the sequences shown are the spacers placed between pseudogenes.
  • SynVH45 is set forth in SEQ ID NO: 16; SynVH46 is set forth in SEQ ID NO: 17;
  • SynVH5l is set forth in SEQ ID NO: 20; SynVH52 is set forth in SEQ ID NO: 21; SynVH53 is set forth in SEQ ID NO: 22; SynVH54 is set forth in SEQ ID NO: 23;
  • SynVH57 is set forth in SEQ ID NO: 26; HuVDJ is set forth in SEQ ID NO: 27; SynVH58 is set forth in SEQ ID NO: 28; SynVH59 is set forth in SEQ ID NO: 29; SynVH60 is set forth in SEQ ID NO: 30; SynVH6l is set forth in SEQ ID NO: 31; SynVH62 is set forth in SEQ ID NO: 32; SynVH63 is set forth in SEQ ID NO: 33; SynVH64 is set forth in SEQ ID NO: 34; SynVH65 is set forth in SEQ ID NO: 35; SynVH70 is set forth in SEQ ID NO: 36; SynVH7l is set forth in SEQ ID NO: 37; SynVH72 is set forth in SEQ ID NO: 38;
  • SynVH73 is set forth in SEQ ID NO: 39; SynVH74 is set forth in SEQ ID NO: 40)
  • FIG. 9 depicts Shannon entropy for all of the aligned V region sequences from SynVH-C and SynVH-SD. The top 1000 sequences from each bird were included. CDR designations (IMGT) are indicated.
  • FIG. 10 Strategy for CRISPR targeting.
  • A Diagram of the chicken IgH locus present in PGC line 472-138 used for CRISPR targeting.
  • the IgH locus contained a previously obtained knockout of the JH gene segment (JH-KO), between the D cluster and the constant regions (only Cp is shown), which was replaced with a selectable marker cassette.
  • gRNAs 1 through 4 were designed to target a region upstream of the single functional VH region (indicated with an arrow), and gRNA5 was designed to target the EGFP gene.
  • B PGCs of line 472-138 were transiently transfected with a construct containing Cas9 or Cas9/gRNA5, specific for EGFP. After 9 days in culture, the cells were analyzed by flow cytometry for loss of green fluorescence.
  • FIG. 11 CRISPR-mediated targeting of IgH K06B in PGCs.
  • A Detailed diagram of the IgH locus. The 122 bp sequence between the 5’ and 3’ homology regions in IgH K06B, used to design the gRNAs, is shown at top. The locations of gRNAs 1-4 are indicated with blue lines above the sequence and the protospacer adjacent motifs (PAM) indicated with red lines.
  • the repair vector IgH K06B (below) contains 5’ and 3’ homology regions (HR) in yellow, a single loxP site (blue arrowhead), and a hygromycin selection cassette (orange). The locations of the primer binding sites for the 5’ and 3’ targeting assays are shown as black arrows.
  • the downstream selectable markers in the JH-KO consist of Boxed EGFP (green box) and puro gene (blue box), and a promoterless neo gene in opposite orientation (pink box).
  • the loxP sites are blue arrowheads.
  • B. The 5’ targeting assay performed on independent, non-clonal cell populations obtained from co-transfection of the four different gRNAs into 472-138 cells along with Cas9 and IgH K06B. For each gRNA transfection, 3 hygromycin-resistant populations were analyzed.
  • the positive control (+) was a DT40 cell line that contained a knockout of the functional V region [22] and the negative control (-) was the parental IgH K06B plasmid.
  • the 5’ and 3’ targeting assays performed on 9 independent clones obtained with gRNA2 (there were 12 clones, but clones 4, 7 and 12 grew more slowly and were not tested at this time). Variation in band intensity is likely to be from variation in the template gDNA amount, since the number of cells harvested was not normalized.
  • the negative control (-) was genomic DNA from a JH-KO transgenic bird, and the positive control (+) was a pool of cells (G2) from the gRNA2 experiment in B. NT, no template control.
  • the same 5’ and 3’ targeting assays performed on EGFP+ birds obtained from breeding cell line 1783-10 chimeras to wild type.
  • FIG. 12 Cre recombination of CRISPR-targeted loxP site A. Diagram of the targeted IgH locus before and after Cre recombination. A forward primer upstream of the CRISPR- targeted loxP site was used with two different reverse primers downstream of the loxP site in the JH-KO cassette. In the nonrecombined allele, the forward and reverse primers are separated by about 28kb on the chromosome. After Cre recombination, a single loxP site and the promoterless neo gene remain, and the primers are either 1.6 or 2kb apart, which amplifies readily. B. PCR of recombined cells. Cre +: gDNA template from 1783-9 cells transfected with Cre; Cre -, parental 1783-9 cells; JH-KO, gDNA from a heterozygous JH- KO bird; NTC, no template control.
  • transgenic chicken refers to an animal comprising cells containing foreign nucleic acid (i.e., recombinant nucleic acid that is not native to the chicken).
  • the foreign nucleic acid should be present in all cells of the chicken with the potential exception of some of the haploid germ cells.
  • the foreign nucleic acid molecule is called a“transgene” and may contain one or many genes, etc., that are not from chicken.
  • a transgenic chicken is able to transmit the foreign nucleic acid stably in its germline.
  • intron refers to a sequence of DNA found in the middle of many gene sequences in most eukaryotes. These intron sequences are transcribed, but removed from within the pre-mRNA transcript before the mRNA is translated into a protein. This process of intron removal occurs by splicing together of the sequences (exons) on either side of the intron.
  • operably-linked refers to the association of nucleic acid sequences on a single nucleic acid fragment so that the function of one is affected by the other.
  • a promoter is operably-linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., the coding sequence is under the transcriptional control of the promoter).
  • an intron is operably-linked to a coding sequence, the intron is spliced out of the mRNA to provide for expression of the coding sequence.
  • two nucleic acids sequences are operably linked if one sequence can“donate” sequence to the other by gene conversion.
  • the donating sequences may be upstream or downstream of the other, and the two sequences may be proximal to each other, i.e., in that there are no other intervening genes.
  • Unlinked means that the associated genetic elements are not closely associated with one another and the function of one does not affect the other.
  • pseudogene is used to describe an untranscribed nucleic acid region that contains an open reading frame that may or may not contain a start and/or a stop codon.
  • An amino acid sequence may be“encoded” by a pseudogene in the sense that the nucleotide sequence of the open reading frame can be translated in silico to produce an amino acid sequence.
  • pseudogenes do not contain promoter regions, recombination signal sequences or leader sequences.
  • transgenic animal may be homozygous or heterozygous for a transgene.
  • endogenous indicates that the gene is native to a cell, i.e., the gene is present at a particular locus in the genome of a non-modified cell.
  • An endogenous gene may be a wild type gene present at that locus in a wild type cell (as found in nature).
  • An endogenous gene may be a modified endogenous gene if it is present at the same locus in the genome as a wild type gene.
  • An example of such a modified endogenous gene is a gene into which a foreign nucleic acid is inserted.
  • An endogenous gene may be present in the nuclear genome, mitochondrial genome etc.
  • construct refers to a recombinant nucleic acid, generally recombinant DNA, that has been generated for the purpose of the expression of a specific nucleotide sequence(s), or is to be used in the construction of other recombinant nucleotide sequences.
  • a construct might be present in a vector or in a genome.
  • recombinant refers to a polynucleotide or polypeptide that does not naturally occur in a host cell.
  • a recombinant molecule may contain two or more naturally- occurring sequences that are linked together in a way that does not occur naturally.
  • a recombinant cell contains a recombinant polynucleotide or polypeptide. If a cell receives a recombinant nucleic acid, the nucleic acid is“exogenous” to the cell.
  • selectable marker refers to a protein capable of expression in a host that allows for ease of selection of those hosts containing an introduced nucleic acid or vector.
  • selectable markers include, but are not limited to, proteins that confer resistance to antimicrobial agents (e.g., hygromycin, bleomycin, or chloramphenicol), proteins that confer a metabolic advantage, such as a nutritional advantage on the host cell, as well as proteins that confer a functional or phenotypic advantage (e.g., cell division) on a cell.
  • expression refers to the process by which a polypeptide is produced based on the nucleic acid sequence of a gene.
  • the process includes both transcription and translation.
  • the term“introduced” in the context of inserting a nucleic acid sequence into a cell means“transfection”, or‘transformation” or“transduction” and includes reference to the incorporation of a nucleic acid sequence into a eukaryotic or prokaryotic cell wherein the nucleic acid sequence may be incorporated into the genome of the cell (e.g., chromosome, plasmid, plastid, or mitochondrial DNA), converted into an autonomous replicon, or transiently expressed (e.g., transfected mRNA).
  • coding sequence refers to a nucleic acid sequence encodes part of a protein, when placed under the control of appropriate regulatory elements.
  • a coding sequence as used herein may have a continuous ORF, may be part of an ORF or might have an ORF interrupted by the presence of introns or non-coding sequences. Pseudogenes may contain an untranscribed coding sequence.
  • the term“in reverse orientation to” refers to coding sequences that are on different strands. For example, if a transcribed region is described as being in reverse orientation to a pseudogene, then the amino acid sequence encoded by the transcribed region is encoded by the top or bottom strand and the amino acid sequence encoded by the pseudogene is encoded by the other strand relative to the transcribed region.
  • antibody and“immunoglobulin” are used interchangeably herein. These terms are well understood by those in the field, and refer to a protein consisting of one or more polypeptides that specifically binds an antigen.
  • One form of antibody constitutes the basic structural unit of an antibody. This form is a tetramer and consists of two identical pairs of antibody chains, each pair having one light and one heavy chain. In each pair, the light and heavy chain variable regions are together responsible for binding to an antigen, and the constant regions are responsible for the antibody effector functions.
  • the recognized immunoglobulin polypeptides include the kappa and lambda light chains and the alpha, gamma (IgGi, IgCT, IgCT, IgG 4 ), delta, epsilon and mu heavy chains or equivalents in other species.
  • Full-length immunoglobulin "light chains" (of about 25 kDa or about 214 amino acids) comprise a variable region of about 110 amino acids at the NfF- terminus and a kappa or lambda constant region at the COOH-terminus.
  • Full-length immunoglobulin "heavy chains” (of about 50 kDa or about 446 amino acids), similarly comprise a variable region (of about 116 amino acids) and one of the aforementioned heavy chain constant regions, e.g., gamma (of about 330 amino acids).
  • antibodies and“immunoglobulin” include antibodies or
  • immunoglobulins of any isotype fragments of antibodies which retain specific binding to antigen, including, but not limited to, Fab, Fv, scFv, and Fd fragments, chimeric antibodies, humanized antibodies, single-chain antibodies, and fusion proteins comprising an antigen binding portion of an antibody and a non- antibody protein.
  • the antibodies may be detectably labeled, e.g., with a radioisotope, an enzyme which generates a detectable product, a fluorescent protein, and the like.
  • the antibodies may be further conjugated to other moieties, such as members of specific binding pairs, e.g., biotin (member of biotin- avidin specific binding pair), and the like.
  • the antibodies may also be bound to a solid support, including, but not limited to, polystyrene plates or beads, and the like. Also encompassed by the term are Fab’, Fv, F(ab’)2, and or other antibody fragments that retain specific binding to antigen, and monoclonal as well as polyclonal antibodies.
  • Antibodies may exist in a variety of other forms including, for example, Fv, Fab, and (Fab')2, as well as bi-functional (i.e. bi-specific) hybrid antibodies (e.g., Lanzavecchia et ak, Eur. J. Immunol. 17, 105 (1987)) and in single chains (e.g., Huston et ak, Proc. Natl. Acad. Sci. U.S.A., 85, 5879-5883 (1988) and Bird et ak, Science, 242, 423-426 (1988), which are incorporated herein by reference).
  • bi-functional hybrid antibodies e.g., Lanzavecchia et ak, Eur. J. Immunol. 17, 105 (1987)
  • single chains e.g., Huston et ak, Proc. Natl. Acad. Sci. U.S.A., 85, 5879-5883 (1988) and Bird et ak, Science, 242,
  • An immunoglobulin light or heavy chain variable region consists of a "framework" region (FR) interrupted by three hypervariable regions, also called“complementarity determining regions” or“CDRs”.
  • the extent of the framework region and CDRs have been precisely defined (see, Lefranc et al, IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res. 2009 vol. 37 (Database issue): D1006-12. Epub 2008 Oct 31; see worldwide website of imgt.org and referred to hereinafter as the“IMGT system”)).
  • the numbering of all antibody amino acid sequences discussed herein conforms to the IMGT system.
  • the sequences of the framework regions of different light or heavy chains are relatively conserved within a species.
  • the framework region of an antibody that is the combined framework regions of the constituent light and heavy chains, serves to position and align the CDRs.
  • the CDRs are primarily responsible for binding to an epitope of an antigen.
  • Chimeric antibodies are antibodies whose light and heavy chain genes have been constructed, typically by genetic engineering, from antibody variable and constant region genes belonging to different species.
  • the variable segments of the genes from a chicken or rabbit monoclonal antibody may be joined to human constant segments, such as gamma 1 and gamma 3.
  • An example of a therapeutic chimeric antibody is a hybrid protein composed of the variable or antigen-binding domain from a chicken or rabbit antibody and the constant or effector domain from a human antibody (e.g., the anti-Tac chimeric antibody made by the cells of A.T.C.C. deposit Accession No. CRL 9688), although other mammalian species may be used.
  • human framework refers to a framework that has an amino acid sequence that is at least 90% identical, e.g., at least 95%, at least 98% or at least 99% identical to the amino acid sequence of a human antibody, e.g., the amino acid sequence of a human germ-line sequence of an antibody.
  • a human framework may be a fully human framework, in which case the framework has an amino acid sequence that is identical to that of a human antibody, e.g., a germ-line antibody.
  • humanized antibody or“humanized immunoglobulin” refers to a non-human antibody containing one or more amino acids (in a framework region, a constant region or a CDR, for example) that have been substituted with a correspondingly positioned amino acid from a human antibody.
  • humanized antibodies are expected to produce a reduced immune response in a human host, as compared to a non- humanized version of the same antibody.
  • humanized antibodies designed and produced by the present method may have additional conservative amino acid substitutions which have substantially no effect on antigen binding or other antibody functions.
  • conservative substitutions is intended combinations such as those from the following groups: gly, ala; val, ile, leu; asp, glu; asn, gln; ser, thr; lys, arg; and phe, tyr.
  • Amino acids that are not present in the same group are“substantially different” amino acids.
  • telomere binding refers to the ability of an antibody to preferentially bind to a particular analyte that is present in a homogeneous mixture of different analytes. In certain embodiments, a specific binding interaction will discriminate between desirable and undesirable analytes in a sample, in some embodiments more than about 10 to lOO-fold or more (e.g., more than about 1000- or 10, 000-fold).
  • the affinity between an antibody and analyte when they are specifically bound in an antibody/analyte complex is characterized by a KD (dissociation constant) of less than 10 6 M, less than 10 7 M, less than 10 8 M, less than 10 9 M, less than 10 9 M, less than 10 11 M, or less than about 10 12 M or less.
  • A“variable region” of a heavy or light antibody chain is an N-terminal mature domain of the chain that contains CDR1, CDR2 and CD3, and framework regions.
  • the heavy and light chain of an antibody both contain a variable domain. All domains, CDRs and residue numbers are assigned on the basis of sequence alignments and structural knowledge. Identification and numbering of framework and CDR residues is as defined by the IMGT system.
  • VH is the variable domain of an antibody heavy chain.
  • VL is the variable domain of an antibody light chain.
  • the term“isolated,” when used in the context of an isolated antibody, refers to an antibody of interest that is at least 60% free, at least 75% free, at least 90% free, at least 95% free, at least 98% free, and even at least 99% free from other components with which the antibody is associated with prior to purification.
  • treatment “treating” and the like are used herein to refer to any treatment of any disease or condition in a mammal, e.g. particularly a human or a mouse, and includes: a) preventing a disease, condition, or symptom of a disease or condition from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it; b) inhibiting a disease, condition, or symptom of a disease or condition, e.g., arresting its development and/or delaying its onset or manifestation in the patient; and/or c) relieving a disease, condition, or symptom of a disease or condition, e.g., causing regression of the condition or disease and/or its symptoms.
  • subject “host,” “patient,” and“individual” are used interchangeably herein to refer to any mammalian subject for whom diagnosis or therapy is desired, particularly humans. Other subjects may include cattle, dogs, cats, guinea pigs, rabbits, rats, mice, horses, and so on.
  • A“natural” antibody is an antibody in which the heavy and light immunoglobulins of the antibody have been naturally selected by the immune system of a multi-cellular organism, as opposed to unnaturally paired antibodies made by e.g. phage display. As such, the certain antibodies do not contain any viral (e.g., bacteriophage Ml3)-derived sequences. Spleen, lymph nodes and bone marrow are examples of tissues that produce natural antibodies in an animal.
  • the term“introduced” in the context of inserting a nucleic acid sequence into a cell means“transfection”, or‘transformation”, or“transduction” and includes reference to the incorporation of a nucleic acid sequence into a eukaryotic or prokaryotic cell wherein the nucleic acid sequence may be present in the cell transiently or may be incorporated into the genome of the cell (e.g., chromosome, plasmid, plastid, or mitochondrial DNA), converted into an autonomous replicon.
  • plurality refers to at least 2, at least 5, at least 10, at least 20, at least 50, at least 100, at least 200, at least 500, at least 1000, at least 2000, at least 5000, or at least 10,000 or at least 50,000 or more. In certain cases, a plurality includes at least 10 to 50. In other embodiments, a plurality may be at least 50 to 1,000.
  • a transgenic chicken that has a modified immunoglobulin heavy chain
  • the modified locus has no endogenous V-D-J region and, instead, has a human VH segment, a human D cluster, a human J segment and a plurality of upstream pseudogenes based on human V H sequences.
  • the modified IgH locus undergoes V(D)J recombination in the chicken, gene conversion between the upstream pseudogenes and the human VH segment occurs, and the chicken produces antibodies that have a diversified immunoglobulin heavy chain.
  • a transgenic chicken comprising a genome comprising a modified endogenous immunoglobulin heavy chain (IgH) locus is provided.
  • This modified locus is schematically illustrated as“SynVH-SD” in Fig. 1.
  • the modified locus lacks the entire contiguous endogenous chicken V-D-J region.
  • This sequence of this locus is currently unknown, but it thought to be in the range of 10-12 kb (e.g., about 11 kb) in length or at least 15 kb (e.g., 15 kb to 25 kb in length or approximately 20 kb in length).
  • the wild type locus does not contain any essential genes (other than the endogenous chicken V-D-J sequences), unlike other animals (e.g., mouse). Removal of the endogenous chicken V-D-J region prevents V(D)J recombination with the V-D-J human sequences described below. Such recombination events would remove much of the locus, thereby inactivating it. Removing the endogenous chicken V-D-J region prevents these events from happening.
  • the locus comprises in operable linkage: (i) an immunoglobulin heavy chain gene promoter, e.g., a chicken immunoglobulin heavy chain gene promoter; (ii) a germline human VH segment, where the germline human VH segment comprises a coding sequence for a variable domain comprising a FR1, a CDR1, a FR2, a CDR2, and a FR3.
  • VH segments are sometimes called “germline VH genes”,“functional VH segments” or“germline VH sequences” in the art.
  • the human germline VH segment can be from the VH3 family, the Vnl family or the VH4 family, for example. Such segments lack heavy chain CDR3 and FR4 coding sequence.
  • the modified locus downstream of the germline human V H segment, also contains a (iii) a human D cluster (i.e., an array of, e.g., 10-27 human Diversity (D) gene segments that can be separated by sequences (i.e., intervening sequences) from the chicken genome as well as a single human Joining (J) segment (e.g., one of the 6 J segments from the human germline, see, e.g., Li et al Blood 2004 103: 4602-4409).
  • D human Diversity
  • J human Joining
  • any codons for a cysteine in the D segments may have been mutated to encode another amino acid, e.g., tyrosine or tryptophan, in order to minimize disulfide bonds in the antibodies (particularly in the heavy chain CDR3 region) produced by the chicken.
  • another amino acid e.g., tyrosine or tryptophan
  • the recombination Signal Sequences (RSSs) flanking the variable (V), diversity (D), and joining (J) genes segments may be from chicken, but the chicken recombinase should recognize human RRSs because the sequences are almost the same.
  • the locus Downstream from the J segment the locus comprises a plurality of sequences encoding constant regions that may be endogenous to the chicken.
  • the locus contains an intron that joins the 3’ end of a transcript of the J segment to the 5’ end of a copy of the constant region coding sequence.
  • the modified locus also contains a plurality of pseudogenes (e.g., at least 10 or 10 to 30 pseudogenes) upstream of the germline human VH segment, where the pseudogenes are of structure FR1-CDR1-FR2-CDR2-FR3, wherein: (i) the FR1, FR2 and FR3 segments in the pseudogenes (i.e., the sequences that“encode” the heavy chain FR1, FR2 and FR3 sequences of an antibody) each have a sequence that is substantially the same as (i.e., having sequences that are at least 95% identical to or identical to) the FR1, FR2 and FR3 segments as the corresponding segments in the germline human VH segment, and (ii) CDR1 and CDR2 sequences, which may encode the CDRls and CDR2s encoded by different human VH segments that are in the same family as the human germline VH segment.
  • pseudogenes e.g., at least 10 or 10 to 30 pseudo
  • the pseudogene will contain the FR1, FR2 and FR3 sequences from that segment, and CDR1/CDR2 sequences from other human germline VH segment in the VH3 family.
  • the pseudogene will contain the FR1, FR2 and FR3 sequences from that segment, and CDR1/CDR2 sequences from other human germline VH segment in the VH! family, etc.
  • the pseudogenes are in reverse orientation to the germline human VH segment.
  • the germline human VH segment may be the selected from the following sequences: VH1-18, VH1-2, VH1-24, VH1-3, VH1-45, VH1-46, VH1-58, VH1-69, VH1-8, VH2-26, VH2-5, VH2-70, VH3-11, VH3-13, VH3-15, VH3-16, VH3-20, VH3-21, VH3-23, VH3-30, VH3-33, VH3-35, VH3-38, VH3-43, VH3-48, VH3-49, VH3-53, VH3-64, VH3- 66, VH3-7, VH3-72, VH3-73, VH3-74, VH3-9, VH4-28, VH4-31, VH4-34, VH4-39, VH4- 4, VH4-59, VH4-61, VH5-51, VH6-1, and VH7-81. See PCT WO 2005/005604 for
  • the FW segments of the human germline VH segment and the pseudogenes may be identical to one another, while the CDR segments of the human germline VH segment and the pseudogenes may differ, thereby allowing gene conversion to occur between the CDR segments of the pseudogenes and the germline sequence.
  • the CDRs may vary in length.
  • the heavy chain CDR1 may be in the range of 6 to 12 amino acid residues in length
  • the heavy chain CDR2 may be in the range of 4 to 12 amino acid residues in length
  • the heavy chain CDR3 may be in the range of 3 to 25 amino acid residues in length, although antibodies having CDRs of lengths outside of these ranges are envisioned.
  • the modified IgH locus undergoes V(D)J recombination in the chicken, the plurality of germline human VH pseudogenes, after V(D)J recombination, donate nucleotide sequences to the germline human VH segment (to at least the CDR1 and CDR2 coding sequence in the germline human VH segment) by gene conversion; and the chicken produces antibodies that comprise a diversified immunoglobulin heavy chain.
  • the antibodies produced by the chicken are diversified in the heavy chain CDR1, CDR2 and CDR3 regions, and the median length of the heavy chain CDR3 is 11-13, e.g., about 12 residues.
  • the CDR3 region is diversified by the D segment selected by V(D)J recombination and somatic hypermutation.
  • the lack of TdT in chickens limits the length of the heavy chain CDR3 to what is encoded by the D genes and/or what could be inserted by gene conversion and, as such, the heavy chain CDR3 is relatively short, relative to wild type chicken and human antibodies and few D-D joins were observed.
  • the chicken may be homozygous for the modified IgH locus, or heterozygous for the modified IgH locus. If this chicken is or heterozygous for the modified IgH locus, the endogenous IgH locus on the homologous chromosome may be knocked out. For example, in some embodiments, the endogenous IgH locus on the homologous chromosome may lack its J region or its entire contiguous endogenous chicken V-D-J region. The chicken may also be heterozygous for a wild type IgH locus.
  • the transgenic chicken may also express an immunoglobulin light chain V region linked to a chicken light chain constant region or a human V region linked to a human light chain constant region, e.g., a human immunoglobulin light chain, such that the antibodies produced by the chicken are fully human or chimeric light chains with a human V region and chicken constant region.
  • an immunoglobulin light chain V region linked to a chicken light chain constant region or a human V region linked to a human light chain constant region e.g., a human immunoglobulin light chain
  • an antibody produced by a subject transgenic animal may contain a chicken constant domain and variable domains that are human. Since an endogenous constant region may be employed in these embodiments, the antibody may still undergo class switching and affinity maturation, which allows the animal to undergo normal immune system development, and mount normal immune responses.
  • an endogenous constant region may be employed in these embodiments, the antibody may still undergo class switching and affinity maturation, which allows the animal to undergo normal immune system development, and mount normal immune responses.
  • transgenic chickens have three endogenous constant regions in the heavy chain locus encoding IgM, IgY and IgA.
  • IgM immunoglobulin M
  • IgY provides humoral immunity to both adults and neonatal chicks which receive about 200 mg of IgY via a reserve deposited into egg yolk.
  • IgA is found primarily in lymphoid tissues (e.g., the spleen, Peyer’s patches and Harderian glands) and in the oviduct although a small amount is transferred into eggs and subsequently taken up by the developing embryo.
  • a transgenic chicken lacking its entire contiguous endogenous chicken V-D-J region in one or both of its homologous chromosomes, as described above, is also provided.
  • a B cell derived from the transgenic chicken is also provided.
  • a method of making the transgenic chicken comprises: (a) removing the entire contiguous endogenous chicken V-D-J region from the immunoglobulin heavy chain (IgH) locus of a chicken; and (b) inserting into the locus a construct comprising: (i) an immunoglobulin heavy chain gene promoter; (ii) a germline human VH segment comprising a coding sequence for a variable domain comprising a FR1, a CDR1, a FR2, a CDR2, and a FR3; (iii) a human D cluster; (iv) a human J segment; and (vi) a plurality of pseudogenes that each comprise: substantially the same FR1, FR2 and FR3 coding sequences as the functional human VH segment of (b)(ii); and CDR1 and CDR2 coding sequences. Steps (a) and (b) can be done in any order.
  • non-coding sequences may be retained in endogenous configuration in order to preserve endogenous regulatory elements that may be contained within.
  • antigens against an antigen can be readily obtained by immunizing the animal with the antigen.
  • antigens include, microorganism, e.g. viruses and unicellular organisms (such as bacteria and fungi), alive, attenuated or dead, fragments of the microorganisms, or antigenic molecules isolated from the microorganisms.
  • this method may comprise: (a) immunizing a transgenic chicken as described above with an antigen; and (b) obtaining from the transgenic chicken an antibody, e.g., a polyclonal or monoclonal antibody, that specifically binds to the antigen.
  • the method may comprise (c) making hybridomas using B cells of the transgenic chicken; and (d) screening said hybridomas to identify a hybridoma that produces an antibody that specifically binds to the antigen.
  • the method may further comprise using PCR to amplify the heavy and light chain variable region-encoding nucleic acid from B cells of the transgenic animal, and expressing a recombinant antibody using said amplified nucleic acid.
  • Monoclonal antibodies may also be recovered from the transgenic chickens using the GEM assay (US patents 8030095 and 8415173; Izquierdo et al, 2014), by deep sequencing or any other B cell interrogation technology (see, e.g., Abcellera’s website).
  • the transgenic chicken may be immunized with: GD2, EGF- R, CEA, CD52, CD20, Lym-l, CD6, complement activating receptor (CAR), EGP40,
  • VEGF tumor-associated glycoprotein TAG-72 AFP (alpha-fetoprotein), BLyS (TNF and APOL - related ligand), CA125 (carcinoma antigen 125), CEA (carcinoembrionic antigen), CD2 (T-cell surface antigen), CD3 (heteromultimer associated with the TCR), CD4, CDlla (integrin alpha-L), CD14 (monocyte differentiation antigen), CD20, CD22 (B-cell receptor), CD23 (low affinity IgE receptor), CD25 (IL-2 receptor alpha chain), CD30 (cytokine receptor), CD33 (myeloid cell surface antigen), CD40 (tumor necrosis factor receptor), CD44v6 (mediates adhesion of leukocytes), CD52 (CAMPATH-l), CD80 (costimulator for CD28 and CTLA-4), complement component C5, CTLA, EGFR, eotaxin (cytokine All), HER2/neu, HER3, HLA-DR, HLA-DR10,
  • the antigens can be administered to a transgenic chicken in any convenient manner, with or without an adjuvant, and can be administered in accordance with a predetermined schedule.
  • serum from the immunized transgenic animals can be fractionated for the purification of pharmaceutical grade polyclonal antibodies specific for the antigen.
  • antibodies can also be made by fractionating egg yolks. A concentrated, purified immunoglobulin fraction may be obtained by
  • antibody-producing cells e.g., spleen cells or other cells
  • cDNAs encoding antibodies are cloned by standard molecular biology techniques and expressed in transfected cells.
  • the procedures for making monoclonal antibodies are well established in the art. See, e.g., European Patent Application 0 583 980 Al, U.S. Pat. No. 4,977,081, WO 97/16537, and EP 0 491 057 Bl, the disclosures of which are incorporated herein by reference.
  • In vitro production of monoclonal antibodies from cloned cDNA molecules has been described by Andris-Widhopf et ak, , J Immunol Methods 242:159 (2000), and by Burton,
  • Antibody compositions are provided.
  • the heavy and light chains variable domains of the antibody are naturally paired by the immune system of the animal.
  • Such antibodies may, in certain case, be post-translationally modified (e.g., glycosylated) by the host cell and may have a glycosylation pattern and composition characteristic of the species of transgenic chicken.
  • the antibodies produced by the subject transgenic chicken may be screened to identify an antibody of interest.
  • this method involves producing a plurality of hybrid cells producing monoclonal antibodies using the method described above, and screening the plurality of monoclonal antibodies using one or a combination of a variety of assays.
  • these assays are functional assays, and may be grouped as follows: assays that detect an antibody’s binding affinity or specificity, and assays that detect the ability of an antibody to inhibit a process.
  • a monoclonal antibody identified as having a specific binding activity with an antigen, or an inhibitory activity is termed a monoclonal antibody of interest. Binding assays
  • antibodies are tested for their ability to bind specifically to a substrate.
  • the term“specifically” in the context of antibody binding refers to high avidity and/or high affinity binding of an antibody to a specific antigen i.e., a polypeptide, or epitope.
  • the specific antigen is an antigen (or a fragment or subfraction of an antigen) used to immunize the animal host from which the antibody- producing cells were isolated.
  • Antibody specifically binding an antigen or fragment thereof is stronger than binding of the same antibody to other antigens.
  • Antibodies which bind specifically to a polypeptide may be capable of binding other polypeptides at a weak, yet detectable, level (e.g., 10% or less of the binding shown to the polypeptide of interest). Such weak binding, or background binding, is readily discernible from the specific antibody binding to a subject polypeptide, e.g. by use of appropriate controls.
  • specific antibodies bind to an antigen with a binding affinity of 10 7 M or more, e.g., 10 8 M or more (e.g., 10 9 M, 10 10 , 10 11 , etc.).
  • an antibody with a binding affinity of 10 6 M or less is not useful in that it will not bind an antigen at a detectable level using conventional methodology currently used.
  • antibody samples produced by a library of antibody producing host cells are deposited onto a solid support in a way that each antibody can be identified, e.g. with a plate number and position on the plate, or another identifier that will allow the identification of the host cell culture that produced the antibody.
  • the antibodies of the invention may be screened for immunospecific binding by any method known in the art.
  • the immunoassays which can be used include but are not limited to competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich"
  • immunoassays immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, and protein A immunoassays, to name but a few.
  • assays are routine and well known in the art (see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York, which is incorporated by reference herein in its entirety). Exemplary immunoassays are described briefly below (but are not intended by way of limitation).
  • Immunoprecipitation protocols generally involve lysing a population of cells in a lysis buffer such as RIPA buffer (1% NP-40 or Triton X-100, 1% sodium deoxycholate,
  • the ability of the antibody of interest to immunoprecipitate a particular antigen can be assessed by, e.g., western blot analysis.
  • One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the binding of the antibody to an antigen and decrease the background (e.g., pre clearing the cell lysate with sepharose beads).
  • Western blot analysis generally involves preparation of protein samples followed by electrophoresis of the protein samples in a polyacrylamide gel (e.g., 8%-20% SDS-PAGE depending on the molecular weight of the antigen), and transfer of the separated protein samples from the polyacrylamide gel to a membrane such as nitrocellulose, PVDF or nylon. Following transfer, the membrane is blocked in blocking solution (e.g., PBS with 3% BSA or non-fat milk), washed in washing buffer (e.g., PBS-Tween 20), and incubated with primary antibody (the antibody of interest) diluted in blocking buffer.
  • blocking solution e.g., PBS with 3% BSA or non-fat milk
  • washing buffer e.g., PBS-Tween 20
  • the membrane is washed in washing buffer, incubated with a secondary antibody (which recognizes the primary antibody, e.g., an anti-human antibody) conjugated to an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) or radioactive molecule (e.g., 32P or 1251), and after a further wash, the presence of the antigen may be detected.
  • a secondary antibody which recognizes the primary antibody, e.g., an anti-human antibody conjugated to an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) or radioactive molecule (e.g., 32P or 1251), and after a further wash, the presence of the antigen may be detected.
  • an enzymatic substrate e.g., horseradish peroxidase or alkaline phosphatase
  • radioactive molecule e.g., 32P or 1251
  • ELISAs involve preparing antigen, coating the well of a 96 well microtiter plate with the antigen, adding the antibody of interest conjugated to a detectable compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) to the well and incubating for a period of time, and detecting the presence of the antigen.
  • a detectable compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase)
  • a detectable compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase)
  • a second antibody conjugated to a detectable compound may be added following the addition of the antigen of interest to the coated well.
  • the binding affinity of an antibody to an antigen and the off-rate of an antibody- antigen interaction can be determined by competitive binding assays.
  • a competitive binding assay is a radioimmunoassay comprising the incubation of labeled antigen (e.g., 3H or 1251) with the antibody of interest in the presence of increasing amounts of unlabeled antigen, and the detection of the antibody bound to the labeled antigen.
  • the affinity of the antibody of interest for a particular antigen and the binding off-rates can be determined from the data by scatchard plot analysis. Competition with a second antibody can also be determined using radioimmunoassays.
  • the antigen is incubated with antibody of interest conjugated to a labeled compound (e.g., 3H or 1251) in the presence of increasing amounts of an unlabeled second antibody.
  • a labeled compound e.g., 3H or 1251
  • Antibodies of the invention may be screened using immunocytochemisty methods on cells (e.g., mammalian cells, such as CHO cells) transfected with a vector enabling the expression of an antigen or with vector alone using techniques commonly known in the art.
  • cells e.g., mammalian cells, such as CHO cells
  • Antibodies that bind antigen transfected cells, but not vector-only transfected cells, are antigen specific.
  • the assay is an antigen capture assay, and an array or microarray of antibodies may be employed for this purpose.
  • Methods for making and using microarrays of polypeptides are known in the art (see e.g. U.S. patents 6,372,483, 6,352,842, 6,346,416 and 6,242,266).
  • the assay measures the specific inhibition of an antibody to an interaction between a first compound and a second compound (e.g. two biopolymeric compounds) or specifically inhibits a reaction (e.g. an enzymatic reaction).
  • one interaction substrate usually a biopolymeric compound such as a protein e.g. a receptor
  • Antibody is added to the reaction vessel followed by a detectable binding partner for the substrate, usually a biopolymeric compound such as a protein e.g. a radiolabeled ligand for the receptor.
  • interaction inhibition may be measured by determining the amount of detectable binding partner present in the vessel. Interaction inhibition occurs when binding of the binding partner is reduced greater than about 20%, greater than about 50%, greater than about 70%, greater than about 80%, or greater than about 90% or 95% or more, as compared to a control assay that does not contain antibody.
  • an enzyme may be bound to a solid support in a reaction vessel.
  • Antibody is usually added to the reaction vessel followed by a substrate for the enzyme.
  • the products of the reaction between the enzyme and the substrate are detectable, and, after a certain time, the reaction is usually stopped. After the reaction has been stopped, reaction inhibition may be measured by determining the level of detectable reaction product present in the vessel. Reaction inhibition occurs when the rate of the reaction is reduced greater than about 20%, greater than about 50%, greater than about 70%, greater than about 80%, or greater than about 90% or 95% or more, as compared to a control assay that does not contain antibody.
  • the monoclonal antibodies are tested in vivo.
  • the method involves administering a subject monoclonal antibody to an animal model for a disease or condition and determining the effect of the monoclonal antibody on the disease or condition of the model animal.
  • In vivo assays of the invention include controls, where suitable controls include a sample in the absence of the monoclonal antibody.
  • suitable controls include a sample in the absence of the monoclonal antibody.
  • a plurality of assay mixtures is run in parallel with different antibody concentrations to obtain a differential response to the various concentrations.
  • one of these concentrations serves as a negative control, i.e. at zero concentration or below the level of detection.
  • a monoclonal antibody of interest is one that modulates, i.e., reduces or increases a symptom of the animal model disease or condition by at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 80%, at least about 90%, or more, when compared to a control in the absence of the antibody.
  • a monoclonal antibody of interest will cause a subject animal to be more similar to an equivalent animal that is not suffering from the disease or condition.
  • Monoclonal antibodies that have therapeutic value that have been identified using the methods and compositions of the invention are termed“therapeutic” antibodies.
  • nucleic acids encoding the monoclonal antibody of interest may be identified if the host cell expressing the monoclonal antibody of interest is identified.
  • the subject nucleic acids may be identified by a variety of methods known to one of skill in the art. Similar methods are used to identify host cell cultures in monoclonal antibody production using hybridoma technology (Harlow et ak, Antibodies: A Laboratory Manual, First Edition (1988) Cold spring Harbor, N.Y.).
  • the host cell expressing the antibody of interest may be identified using a“look-up” table which lists, for every antibody sample, the corresponding host cell culture.
  • a look-up table containing antibody library sample identifiers, corresponding expression cassette library sample identifiers and/or host cell identifiers may be used to identify the subject nucleic acids.
  • nucleic acids encoding a monoclonal antibody of interest may be recovered, characterized and manipulated using techniques familiar to one of skill in the art (Ausubel, et al, Short Protocols in Molecular Biology, 3rd ed., Wiley & Sons, (1995) and Sambrook, et al, Molecular Cloning: A Laboratory Manual, Third Edition, (2001) Cold Spring Harbor, N.Y.).
  • the methods of producing a monoclonal antibody of interest involve transferring identified expression cassettes for a monoclonal antibody of interest into a suitable vector, and transferring the recombinant vector into a host cell to provide for expression of the monoclonal antibody.
  • the subject methods involve transferring at least the variable domain-encoding sequences from the identified heavy and light chains into vectors suitable for their expression in immunoglobulin heavy and light chains. Suitable constant domain-encoding sequences and/or other antibody domain-encoding sequences may be added to the variable domain-encoding sequences at this point. These nucleic acid modifications may also allow for humanization of the subject antibody.
  • the subject monoclonal antibodies can be produced by any method known in the art for the synthesis of antibodies, in particular, by recombinant expression techniques.
  • Recombinant expression of a subject monoclonal antibody, or fragment, derivative or analog thereof usually requires construction of an expression vector containing a polynucleotide that encodes the antibody.
  • Methods which are well known to those skilled in the art can be used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques and synthetic techniques.
  • the invention provides vectors comprising a nucleotide sequence encoding an antibody molecule of the invention.
  • the expression vector is transferred to a host cell by conventional techniques and the transfected cells are then cultured to produce a subject antibody.
  • vectors encoding both the heavy and light chains are co-expressed in the host cell to provide for expression of the entire immunoglobulin molecule.
  • a variety of host-expression vector systems may be utilized to express a subject monoclonal antibody. These include but are not limited to microorganisms such as bacteria (e.g., E. coli, B. subtilis) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., Saccharomyces, Pichia) transformed with recombinant yeast expression vectors containing antibody coding sequences; insect cell systems infected with recombinant vims expression vectors (e.g., baculovirus) containing antibody coding sequences; plant cell systems infected with recombinant vims expression vectors (e.g., cauliflower mosaic vims, CaMV; tobacco mosaic vims, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS
  • bacterial cells such as Escherichia coli, and eukaryotic cells are used for the expression of entire recombinant antibody molecules.
  • mammalian cells such as Chinese hamster ovary cells (CHO), in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovims is an effective expression system for antibodies (Foecking et ak, Gene 45:101 (1986); Cockett et ak, Bio/Technology 8:2 (1990)).
  • a number of expression vectors may be selected depending upon the use intended for the antibody molecule being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of an antibody molecule, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable.
  • vectors include, but are not limited, to the E. coli expression vector pUR278 (Ruther et ak, EMBO J. 2:1791 (1983)), in which the antibody coding sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, Nucleic Acids Res.
  • pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST).
  • GST glutathione S-transferase
  • fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to matrix glutathione- agarose beads followed by elution in the presence of free glutathione.
  • the pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.
  • Autographa califomica nuclear polyhedrosis virus (AcNPV) is used as a vector to express antibodies.
  • the virus grows in Spodoptera frugiperda cells.
  • the antibody coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the vims and placed under control of an AcNPV promoter (for example the polyhedrin promoter).
  • a number of viral-based expression systems may be utilized to express a subject antibody.
  • the antibody coding sequence of interest may be ligated to an adenovirus
  • transcription/translation control complex e.g., the late promoter and tripartite leader sequence.
  • This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region El or E3) will result in a recombinant virus that is viable and capable of expressing the antibody molecule in infected hosts (e.g., see Logan & Shenk, Proc. Natl. Acad. Sci. USA 81:355-359 (1984)). The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bittner et ak, Methods in Enzymol. 153:51-544 (1987)).
  • stable expression may be used.
  • cell lines which stably express the antibody molecule may be engineered.
  • host cells can be transformed with immunoglobulin expression cassettes and a selectable marker.
  • engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media.
  • the selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into a chromosome and grow to form foci which in turn can be cloned and expanded into cell lines.
  • Such engineered cell lines may be particularly useful in screening and evaluation of compounds that interact directly or indirectly with the antibody molecule.
  • a number of selection systems may be used, including but not limited to the herpes simplex vims thymidine kinase (Wigler et al., Cell 11:223 (1977)), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci.
  • adenine phosphoribosyltransferase genes can be employed in tk-, hgprt- or aprt-cells, respectively.
  • antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et ak, Natl. Acad. Sci. USA 77:357 (1980); O'Hare et ak, Proc. Natl. Acad. Sci.
  • the host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide.
  • the two vectors may contain different selectable markers and origins of replication, which enable equal expression of heavy and light chain polypeptides.
  • a single vector may be used which encodes, and is capable of expressing, both heavy and light chain polypeptides.
  • an antibody molecule of the invention may be purified by any method known in the art for purification of an immunoglobulin molecule, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins.
  • chromatography e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography
  • centrifugation e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography
  • differential solubility e.g., differential solubility, or by any other standard technique for the purification of proteins.
  • antibodies are secreted from the cell into culture medium and harvested from the culture medium.
  • Utility Also provided is a method for modulating or treating at least one antigen-related disease, in a cell, tissue, organ, animal, or patient, as known in the art or as described herein, using at least one antibody of the present invention, e.g., administering or contacting the cell, tissue, organ, animal, or patient with a therapeutic effective amount of antibody.
  • the present invention also provides a method for modulating or treating at least one antigen related disease, in a cell, tissue, organ, animal, or patient including, but not limited to, at least one of obesity, an immune related disease, a cardiovascular disease, an infectious disease, a malignant disease or a neurologic disease.
  • treatment of pathologic conditions is effected by administering an effective amount or dosage of at least one antibody composition that total, on average, a range from at least about 0.01 to 500 milligrams of at least one antibody per kilogram of patient per dose, and, preferably, from at least about 0.1 to 100 milligrams
  • the effective serum concentration can comprise 0.1-5000 ng/ml serum concentration per single or multiple administration ⁇ Suitable dosages are known to medical practitioners and will, of course, depend upon the particular disease state, specific activity of the composition being administered, and the particular patient undergoing treatment. In some instances, to achieve the desired therapeutic amount, it can be necessary to provide for repeated administration, i.e., repeated individual administrations of a particular monitored or metered dose, where the individual administrations are repeated until the desired daily dose or effect is achieved.
  • a subject antibody can, in certain embodiments also be used in diagnostics where the antibody is conjugated to a detectable markers or used as primary antibodies with secondary antibodies that are conjugated to detectable markers.
  • Detectable markers include radioactive and non-radioactive labels and are well-known to those with skill in the art. Common non radioactive labels include detectable enzymes such as horseradish peroxidase, alkaline phosphatase and fluorescent molecules. Fluorescent molecules absorb light at one wavelength and emit it at another, thus allowing visualization with, e.g., a fluorescent microscope. Spectrophotometers, fluorescence microscopes, fluorescent plate readers and flow sorters are well-known and are often used to detect specific molecules which have been made fluorescent by coupling them covalently to a fluorescent dye. Fluorochromes such as green fluorescent protein, red shifted mutants of green fluorescent protein, amino coumarin acetic acid (AMCA), fluorescein isothiocyanate (FITC), tetramethylchodamine
  • the molecules can be used in cell isolation strategies such as fluorescence-activated cell sorting (FACS) if fluorescent markers are used.
  • FACS fluorescence-activated cell sorting
  • cells tagged with fluorescent molecules are sorted electronically on a flow cytometer such as a Becton-Dickinson (San Jose, Calif.) FACS IV cytometer or equivalent instrument.
  • the fluorescent molecules are antibodies that recognize specific cell surface antigens.
  • the antibodies are conjugated to fluorescent markers such as fluorescein isothiocyanate (FITC) or Phycoerythrin (PE).
  • Embodiment 1 A transgenic chicken, wherein the transgenic chicken comprises a genome comprising a modified endogenous immunoglobulin heavy chain (IgH) locus that:
  • variable domain that comprises FR1, CDR1, FR2, CDR2, and FR3 sequences
  • the modified IgH locus undergoes V(D)J recombination in the chicken
  • the plurality of germline human VH pseudogenes after V(D)J recombination, donate nucleotide sequences to the germline human VH segment by gene conversion;
  • Embodiment 2 The transgenic chicken of embodiment 1, wherein the CDR1 and CDR2 sequences of (b)(vi) that encode the CDRls and CDR2s of different human VH segments that are in the same family as the functional human VH segment of (b)(ii).
  • Embodiment 3 The transgenic chicken of any prior embodiment, wherein the entire contiguous endogenous chicken V-D-J region of (a) is at least 15 kb in length.
  • Embodiment 4 The transgenic chicken of any prior embodiment, wherein the promoter of (b)(i) is a chicken immunoglobulin heavy chain gene promoter.
  • Embodiment 5 The transgenic chicken of any prior embodiment, wherein the germline human VH segment of (b)(ii) and the CDR1 and CDR2 sequences of (vi) are from the VH3 family, the Vul family or the VH4 family.
  • Embodiment 6 The transgenic chicken of any prior embodiment, wherein, in the D cluster, any codons for a cysteine have been mutated to encode another amino acid.
  • Embodiment 7 The transgenic chicken of embodiment 6, wherein, in the D cluster, any codons for a cysteine have been mutated to encode tyrosine or tryptophan.
  • Embodiment 8 The transgenic chicken of any prior embodiment, wherein the intervening sequences in the D cluster are from chicken.
  • Embodiment 9 The transgenic chicken of any prior embodiment, wherein the plurality of pseudogenes of (b)(v) comprises at least 10 of the pseudogenes.
  • Embodiment 10 The transgenic chicken of any prior embodiment, wherein the pseudogenes of (b)(v) are in reverse orientation to the germline human VH segment of (b)(ii).
  • Embodiment 11 The transgenic chicken of any prior embodiment, wherein the plurality of sequences encoding constant regions of (b)(v) are endogenous to the chicken.
  • Embodiment 12 The transgenic chicken of any prior embodiment, wherein the transcript of the modified immunoglobulin heavy chain (IgH) locus comprises an intron that joins the 3’ end of a copy of the J coding sequence to the 5’ end of a copy of the constant region coding sequence of (b)(v).
  • IgH immunoglobulin heavy chain
  • Embodiment 13 The transgenic chicken of any prior embodiment, wherein the chicken is homozygous for the modified IgH locus.
  • Embodiment 14 The transgenic chicken of any prior embodiment, wherein the chicken is heterozygous for the modified IgH locus and the IgH locus on the homologous chromosome is knocked out.
  • Embodiment 15 The transgenic chicken of any prior embodiment, wherein the chicken is heterozygous for the modified IgH locus and the IgH locus on the homologous chromosome is wild type.
  • Embodiment 16 The transgenic chicken of embodiment 14, wherein the chicken is heterozygous for the modified IgH locus and the IgH locus on the homologous chromosome lacks its entire contiguous endogenous chicken V-D-J region.
  • Embodiment 17 The transgenic chicken of embodiment 14, wherein the chicken is heterozygous for the modified IgH locus and the IgH locus on the homologous chromosome lacks a J region.
  • Embodiment 18 The transgenic chicken of any prior embodiment, wherein the antibodies produced by the chicken are diversified in the heavy chain CDR1, CDR2 and CDR3 regions.
  • Embodiment 19 A transgenic chicken lacking its entire contiguous endogenous chicken V-D-J region in one or both of its homologous chromosomes.
  • Embodiment 20 A B cell derived from the transgenic chicken of any prior embodiment.
  • Embodiment 21 A method comprising:
  • Embodiment 22 The method of embodiment 21, wherein the antibody is polyclonal.
  • Embodiment 23 The method of embodiment 21, wherein the antibody is
  • Embodiment 24 The method of any of embodiments 21-23, further comprising:
  • Embodiment 25 The method of any of embodiments 21-24, further comprising using PCR to amplify the heavy and light chain variable region-encoding nucleic acid from B cells of the transgenic animal, and expressing a recombinant antibody using said amplified nucleic acid.
  • Embodiment 26 An antibody produced by a transgenic chicken of any of embodiments 1-19.
  • Embodiment 27 A method comprising: (a) removing the entire contiguous endogenous chicken V-D-J region from the immunoglobulin heavy chain (IgH) locus of a chicken; and
  • steps (a) and (b) are done in any order.
  • transgenic chickens were engineered to produce a human variable region antibody repertoire.
  • the use of a single V framework in chickens has an advantage because a preferred framework with optimal manufacturing and developability characteristics may be selected.
  • Transgenes can be designed such that diversity is focused in the CDRs, while maintaining germline or near germline framework sequences. The strategy is to retain the advantage of the chicken B cell system for incorporating diversity, using a single human framework with upstream human- based pseudogenes, instead of inserting a large human genomic fragment (carrying multiple human V, D and J genes) which may not be regulated properly in the chicken.
  • the level of diversity produced by the transgene must be sufficient.
  • Two lines of transgenic chickens were produced: one carrying a pre-rearranged, functional VH region that relies entirely on gene conversion/somatic hypermutation to produce diversity, and one which undergoes V(D)J rearrangement first to produce a functional VH region, thereby potentially increasing the level of CDR-H3 diversity, followed by gene conversion/somatic hypermutation.
  • the pre-rearranged VH region construct, SynVH-C was previously described (18).
  • the V(D)J rearranging construct, SynVH-SD was made by gene synthesis of several parts followed by ligation.
  • the V, D and J regions were assembled as follows.
  • the human germline VH3-23*0l gene was the single V gene used, and the JH6 gene was the single J gene.
  • 24 non-redundant human Ds were flanked by recombination signal sequences and intervening regions from the chicken D locus (these spacers were about 100-200 bp each). Cysteine codons in the human D2 family were mutated to encode tyrosine (7 instances) or tryptophan (2 instances).
  • the rearranging elements were cloned with the chicken VH promoter to drive expression of the heavy chain, and a short section of the chicken J-C intron for splicing to the endogenous constant regions was included.
  • the human pseudogenes contained FRs from the human germline VH3-23 gene and CDRs 1 and 2 from the VH3 germline gene family. 13 pseudogenes were designed. Spacer sequences between each pseudogene were from the chicken pseudogene region, but did not include chicken V sequences themselves.
  • An attB site for insertion into the attP site targeted to the chicken heavy chain locus was included (21,22), and a loxP site for later recombination with loxP sites in the target genome.
  • the SynVH-SD construct was transfected into the heavy chain attP-containing cells.
  • a loxP site had previously been inserted by CRISPR- mediated targeting upstream of the chicken VH segment (22).
  • CRISPR- mediated targeting upstream of the chicken VH segment (22).
  • a second loxP site was brought in by the SynVH-SD transgene, in the same orientation as the first loxP site, directly upstream of the human pseudogene array. Breeding to Cre hens removed all of the DNA between the loxP sites, which included the chicken VH and D genes and the selectable markers used during the transfections, leading to the structure shown in Fig. 1.
  • RNA from spleen lymphocytes was extracted using RNeasy (Qiagen). 10-15 ng total RNA was used in a OneStep Ahead (Qiagen) proofreading polymerase reaction using primers chVH-F9 ( 5 -C ACC AGTCGGCTCCGC A ACC ATG-3 (SEQ ID NO: 1)) and clgY- NGS-R (5’ -GGGCGATGTGGGGCTCGC-3’ (SEQ ID NO: 2)).
  • ABM performed paired end merging, cluster analysis, matching of sequences to the previously identified mAh sequences, and CDR-H3 length determination ⁇
  • SynVH-C Human VH sequences from chickens with two different human heavy chain transgenes were analyzed.
  • One of these transgenes, SynVH-C contained a pre-rearranged functional V region (18), and the other, SynVH-SD, contained germline V, D and J segments that undergo rearrangement in B cells (Fig 1).
  • the V region in SynVH-C was obtained from screening a human library and it contained a rearranged VH3-23/D1/JH4 region, with 9 framework (FR) changes relative to the germline VH3-23 gene.
  • the SynVH-SD construct contained a single germline V gene, VH3-23, all of the human D elements, and a single JH6 gene.
  • the D elements were separated by intervening sequences from chicken D locus, including the highly conserved recombination signal sequences. All of the other non-coding sequence (promoter and introns) in both constructs was derived from the chicken heavy chain locus for optimal transcriptional and post-transcriptional regulation.
  • the transgene constructs were inserted into the endogenous heavy chain locus via a combination of gene targeting and integrase-mediated insertion (18,22).
  • the human V regions in both transgenes splice to the endogenous downstream chicken constant regions.
  • Both of the transgenes contained upstream human-based pseudogenes which can participate in gene conversion of the functional human V ((8,11).
  • the pseudogenes were designed with diversity mainly in the CDRs (FIG. 8), although some of the SynVH-C pseudogenes also contain changes in the frameworks. These pseudogenes were designed de novo and bear no relation to the V gene pseudogenes resident in the human genome. Two different approaches to pseudogene CDR design were taken. In SynVH-C, CDRs were derived from naturally occurring CDR sequences found in human sequence databases of expressed sequences (ESTs).
  • the CDRs were from the germline human VH3 family members, CDR1 and 2, with no specific CDR3 sequences in the pseudogenes, since germline V genes do not contain CDR3.
  • Downstream of FR3 were placed the spacer sequences, which are diverse sequences that have the potential to be used in gene conversion even though they are not derived from human CDR3s (Fig. 8). After insertion, the chicken pseudogene array was still present upstream in both cases.
  • Heavy chain V regions were sequenced in bulk by NGS amplicon sequencing from spleen lymphocyte populations of 9 immunized birds (see below for details of
  • VH regions were amplified from lymphocyte RNA following reverse transcription, using a forward primer in the 5’ UTR and a reverse primer in the IgY constant region CH1 domain, and sequenced by MiSeq (Applied Biological Materials, Canada).
  • the primers used to amplify VH regions were chosen so that they would amplify the human V region or the chicken V region, should it be expressed.
  • the human transgenes the only sequence that is human is the V region coding sequence. All of the noncoding sequences (the 5’ UTR, introns, etc.) and the constant region coding sequences were chicken sequence in both SynVH constructs. Paired-end reads were assembled and translated to provide theoretical protein sequence.
  • the number of reads, unique nucleotide and protein sequences from each bird are given in Table 1.
  • the most common sequence in each bird ranged in the number of times it was found from about 6700 to 89,000.
  • the top 1000 most common unique sequences from each sample were used, which represented 34- 62% of the total sequence data from each sample.
  • the numbers of unique nucleotide and protein sequences are given, and the number of unique peptide sequences that were sequenced two or more times (2X depth).
  • the proportion of the total sequence reads represented by the top 1000 sequences is given in the last column.
  • VH regions from the 9 birds started with determining whether the expressed sequences were fully human, as expected, or contained any chicken sequence
  • the signal peptide did not always match the sequence that was introduced in the transgene construct. Although 80-90% of the sequences in SynVH-C and SynVH-SD transgenes contained the human signal peptide fused to human V sequences, sequence variation in the signal peptide was found. Three patterns of changes in the signal peptide were observed. In the first pattern, the intact chicken signal peptide exon was spliced in frame directly to the human V region exon, which was found in approximately 20% of the sequences in SynVH-SD and 5% in SynVH-C (Fig 2 and Table 2). The higher frequency of signal peptide changes in SynVH-SD suggests that there is a selection for such changes.
  • SynVH-SD contains a Lys residue in the central hydrophobic domain, where the SynVH-C contains Ile, which makes it less hydrophobic than either the SynVH-C signal peptide or the chicken VH signal peptide and a less efficient signal peptide (27) (Fig 2).
  • the SynVH-SD signal peptide is identical to the human germline VH3-23 gene, whereas the SynVH-C signal peptide contains the Ile mutation relative to the germline.
  • the portion of the signal peptide encoded in the first exon was human but the 4 amino acids of the signal peptide that are encoded in the V exon were chicken (Fig 2).
  • This pattern was observed in about 15% of the SynVH-SD sequences, but never in SynVH-C. This region is present in some of the chicken pseudogenes (8), so it is likely that gene conversion was responsible for mutating this region of the signal peptide to chicken.
  • the chicken-derived sequence in this region extended slightly farther in these instances, to the third amino acid of the mature VH region (see below).
  • the SynVH-SD sequences retained the full human signal peptide, but carried a point mutation in the Lys residue (Fig 2), changing it to a hydrophobic residue (Val, Ile, or Met). This pattern occurred in about 40% of the SynVH-SD sequences. All three of these types of changes increased the hydrophobicity of the signal peptide. The high prevalence of these different types of changes to the SynVH-SD signal peptide strongly indicates positive selection for these changes.
  • the number (and percentage of total sequences from each transgene) of chicken and human VH regions is shown. Data from the six SynVH-C samples and three SynVH-SD samples were combined (total, 6000 sequences from SynVH-C birds and 3000 sequences from SynVH-SD birds). In the first set of columns are shown the sequences containing the chicken VH, split into those with a chicken signal peptide (Ch sig pep) or human signal peptide (Hu sig pep). In the second set of columns are the sequences with the human VH, similarly split for sequence of signal peptide. All of the sequences had the human JH (right column). The total number of VH regions is slightly less than the total number of sequences because a few sequences had VH deletions.
  • the chicken pseudogene array is still present upstream in both SynVH-C and SynVH-SD transgenes (Fig 1).
  • SynVH-SD the chicken pseudogenes are in closer proximity to the human functional V, immediately upstream of the human pseudogenes, whereas in SynVH-C, the chicken V and D genes are between the two pseudogene arrays.
  • the signal peptide sequence adjacent to FR1 underwent gene conversion in SynVH-SD, so it was interesting to know if further gene conversion of the human frameworks by chicken pseudogenes occurred.
  • the chicken germline VH segment is about 65% identical overall to the V genes in the transgenes.
  • the longest stretches of homology are 11 bp, and mismatches of 1-6 bp are spread throughout the V regions. It is unclear whether this level and pattern of homology would be sufficient to enable gene conversion.
  • FR1 and 3 were analyzed at the protein level for evidence of long stretches of chicken residue replacement (FR2 is too conserved between chicken and human to be able to unequivocally detect gene conversion events). Very low levels of gene conversion of the human FR1 and 3 in SynVH-C (0.07% in FR1 and 0.3% in FR3, in 5652 sequences) and SynVH-SD (2% in FR1 but none in FR3) were observed
  • SynVH-SD FR1 could be a result of a continuation of gene conversion events that began in the signal peptide region at the 5’ end of the gene and continued into FR1.
  • Another potential contributing factor could be the closer physical proximity on the chromosome of the human functional V to the chicken pseudogenes in SynVH-SD since the chicken V and D cluster were deleted in that transgene (Fig 1).
  • the antigen-specific mAh sequences derived from these birds see below, no chicken-derived FR residues were seen in any sequence, which bolsters the idea that these rare gene conversion-derived sequences were not under selection nor were they necessary to produce antigen binders.
  • Gene conversion is defined as a long tract of sequence (i.e. the whole of FR1) that is chicken sequence.
  • the protein sequence was analyzed, not the nucleotide sequence.
  • the number of human sequences analyzed is given at right.
  • ND not determined.
  • Chicken FR2 differs by only one (SynVH-SD) or two (SynVH- C) amino acids from the human transgene and this it was not possible to unequivocally assess gene conversion.
  • CDR3 length diversity was analyzed in the two genotypes, from IMGT positions 105-117.
  • the range was 3-22 amino acids, and the mean was 11.56 ⁇ 2.06 (Fig 3).
  • the CDR-H3 length in the germline of SynVH-C is a fixed length of 11 codons, since it is pre-rearranged, and any variation in length could only be a result of gene conversion or somatic hypermutation that deleted or inserted sequences. These mechanisms were more likely to increase the CDR length, as 55% have lengths longer than 11 residues, yet only 27 % of the sequences have a length less than 11.
  • CDR-H3s tend to be longer than those presented here, with mean CDR-H3 lengths of 15-16 residues, and a normal distribution (17,28,29).
  • WT chickens the broad range of CDR-H3 lengths is produced by a combination of single D usage (the hypothetical range of lengths with no chewing back would be 20-22 codons if a single D is used), tandem D-D joining, exonucleolytic trimming, and gene conversion (6,8,29).
  • Trp which was not present in SynVH-C but found at 3.3% in SynVH-SD, all at IMGT position 38.
  • Trp is found in three of the SynVH-SD pseudogenes, at position 38, but not in any of the SynVH-C pseudogenes.
  • Ala was more prevalent in SynVH-C sequences and reflects the presence of Ala in 15 of the 20 SynVH-C pseudogenes at IMGT position 38.
  • Trp was more frequent in SynVH-SD, and two of the SynVH-SD pseudogenes contain Trp, at IMGT position 58, whereas none of the SynVH-C pseudogenes contains Trp. For Trp to be present in SynVH-C sequences, it could only be caused by somatic hypermutation.
  • the JH6 gene used in SynVH-SD contains a string of 5 Tyr residues which biases the frequency of amino acids in the data toward Tyr and as a consequence reduces the frequency of the other amino acids if the whole CDR is included (regardless of whether the bounds are IMGT positions 105-117 or 107-114).
  • the J gene in SynVH-C is JH4, which is shorter and contains only two Tyr residues.
  • positions in the JH6 gene that encode tyrosine were found to be somatically mutated in SynVH-SD birds and could be highly diverse, such as positions 113 and 114.
  • the lack of diversity at positions 112 and 112A may reflect a reduced involvement of these positions in antigen binding, resulting in less selection pressure for somatic mutation.
  • the lack of specific CDR3 sequences in the SynVH-SD pseudogenes may also have been a contributing factor, although the variability in positions 108-111 and 113-114 was not reduced compared to SynVH-C despite those positions also lacking pseudogene donors.
  • FRs contained little diversity, in particular FR2.
  • FR variability was somewhat lower in SynVH-SD than in SynVH-C, which may be expected since the pseudogenes in SynVH-C contain some FR changes whereas those in SynVH-SD do not. Any changes in the FRs in SynVH-SD must be from non-templated hypermutation, or potentially from chicken pseudogenes.
  • the FR1 variability observed in SynVH-SD was partly from chicken pseudogenes (as discussed above), but the overall level of variability was still lower than that of SynVH-C in FR1.
  • FR2 had essentially no variability.
  • the SynVH-C functional V region contains the motif RLF in FR3 (IMGT positions 90-92) that represents a somatic mutation compared to the germline residues QMN found in the VH3-23 gene.
  • Several of the SynVH-C pseudogenes contain the QMN residues in those positions, enabling a reversion to the germline FR3 sequence by gene conversion. This reversion was observed in 94% of the sequences, strongly suggesting that the RLF motif was structurally disfavored and that the QMN residues were selected in the repertoire.
  • IMGT CDR designations were used.
  • the SynVH-SD transgene had the D cluster which could in principle provide higher cysteine content, the transgene was designed such that the Cys codons normally found in the germline human D2 family members were all mutated to encode Tyr or Trp.
  • the region downstream of the FR3 does contain some Cys codons, so gene conversion (as well as somatic hypermutation) could have added cysteines.
  • the SynVH-SD pseudogene design was based on the germline VH3 family CDRs, and since germline V genes do not contain CDR3, the region downstream of FR3 in the pseudogenes was simply a spacer sequence between pseudogenes. These spacers could provide a potential source of diversity if they are used in gene conversion.
  • the cysteine content of the human sequences from chickens is low, as in human- derived sequences, which is in sharp contrast to the cysteine content of normal chicken antibodies (17).
  • 53% of non-selected VH clones contained two non- canonical cysteines in CDR-H3, compared to 1.3% of the human sequences from chickens. These paired cysteines may form small loops that stabilize the antigen-binding structure in chicken CDR-H3s.
  • the cysteines are separated by 2-4 amino acids in the human sequences presented here, whereas in some cases the loops in chicken antibodies can be longer (17).
  • Chicken VH sequences often contain a single cysteine in CDR3 and a second cysteine elsewhere in the VH region, forming a potential disulfide bridge from CDR3 to another part of the V region (Types 3-6 of Wu et ah). No such paired cysteines were observed in the human sequences from the chicken. Only one sequence out of 8652 from both transgenes had two non-canonical cysteines in different parts of the V region, a single SynVH-C sequence with cysteines in FR2 and FR3. This particular pattern was not seen in chickens (17).
  • parentheses are shown the sequences of the potential loops. The only other potential disulfide loop was a single SynVH-C sequence with Cys residues in FR2 and FR3.
  • FR2 and FR4 all instances of non-canonical Cys were cases of Trp->Cys changes, which can occur by a single nucleotide substitution. No instances of more than 2 non-canonical cysteines were observed. Comparison ofmAbs to NGS data
  • the spleen lymphocytes that were the source of the NGS data came from birds that had been immunized and used to produce antigen-specific antibodies.
  • the six SynVH-C and three SynVH-SD birds were immunized with a test immunogen, human progranulin
  • PGRN Panels of antigen- specific mAbs were identified from each bird, by screening spleen cells in GEM assays (18,39). The mAbs were confirmed as binding to PGRN by ELISA, and sequences of the heavy and light chain V regions were obtained. The light chain in all of these birds was provided by a human V-kappa transgene (18). The birds were heterozygous for both heavy and light chain transgenes, with light and heavy chain knockouts on the other alleles. Therefore only human V-region antibodies are produced in the birds.
  • the unique VH sequences of the antigen-specific mAbs from each individual bird were compared to the NGS data from the same bird (total, 177 mAbs).
  • the number of times each mAh was sequenced in the NGS data is shown in Fig 7. All 177 mAh sequences were found in the NGS data, with varying degrees of matching. 79 of the mAbs (45%) were sequenced 5 times or fewer in the NGS data, and 37 were only sequenced once, indicating that GEM screens can readily identify rare mAbs. If one were to select mAbs based on sequence data alone, one would likely miss these rare mAbs. Others were found multiple times, up to about 7000 times.
  • NGS data represent a snapshot of the spleen, at most about 10 6 B cells (on average, the total number of sequences from each bird that were obtained), whereas the mAbs were derived from a GEM screen of a larger sample size, about 7x106 B cells.
  • the sequence from a single cell picked in a GEM screen might be related to sequences in a family tree in the NGS data although the exact sequence was not found in the NGS data. Sequence errors introduced by reverse transcription or library preparation could also be a factor.
  • the chicken gene conversion/somatic hypermutation system has evolved to produce a diverse repertoire that is capable of conferring protective immunity on its host.
  • the lack of diversity from combinatorial mechanisms does not seem to be a limitation for the CDR-H3 repertoire.
  • two transgenes encoding human variable regions were introduced, one which cannot undergo rearrangement but is forced to generate its sequence diversity purely through gene conversion and/or somatic hypermutation, and the other which undergoes rearrangement and has the choice of all human Ds to produce combinatorial diversity, the levels of amino acid diversity were similar. Because the dataset came from immunized birds, there could be some bias toward specific residues from the immunization, but the two transgenes behaved similarly despite having different modes of diversity generation. In CDRs 1 and 2, and the FRs, it was possible to correlate amino acid frequencies to residues found in the human pseudogenes in both transgenes, but for CDR3, it was not.
  • SynVH-SD did not produce the range of lengths that were theoretically possible by D-D joins or even single D rearrangements. Constraints on CDR-H3 length could come from pairing with the particular V-kappa light chain in the transgenic chickens, potentially unfavorable structural attributes of such human D-D sequences, or unknown s-acting sequences that promote D-D joins in chicken that were not included in the human SynVH- SD construct.
  • Guide RNA design A l59bp region upstream of the chicken functional heavy chain V was analyzed on the MIT server for guide RNA design.
  • Four guide RNAs were selected, synthesized and cloned separately into the GE6 vector containing the wild type Cas9 nuclease (Horizon): gRNAl, AAATCATTAATCAACCCGAC (SEQ ID NO: 43); gRNA2, AACACGACTCCGGGCCTAGA (SEQ ID NO: 44); gRNA3,
  • TGATTAATTGGGCGCCCGTC SEQ ID NO: 45; gRNA4,
  • gRNAs had few predicted off- target sites, none of which were in known coding sequences.
  • a control construct containing gRNA5 specific for EGFP was also made (AAGTTCGAGGGCGACACCC (SEQ ID NO: 47)).
  • Targeting vector IgH K06B design Homology regions of H33bp and 101 lbp were PCR amplified and cloned from a homozygous knockout chicken that carried the original JH-KO (Schusser et al Proc Natl Acad Sci USA. 2013 110: 20170-20175).
  • the 5’ HR was amplified with primers 5’-GCCCCTAATAAGTGGTTTAATTATG-3’ (SEQ ID NO: 48) and 5’ -TCTGCGCTGAGTTCTTTGAT-3’ (SEQ ID NO: 49); the 3’ HR was amplified with primers 5’ - AAGTCGAGGCTGACGAGAAA-3’ (SEQ ID NO: 50) and 5’- CTTTTCCCCACCAAATTTCA-3’ (SEQ ID NO: 51). Homozygous DNA ensured that the homology regions would be isogenic to the allele carrying the JH-KO in the cells used for targeting, 472-138, which are heterozygous for the JH-KO.
  • the two alleles are likely to be polymorphic since the chickens used to derive these PGCs are outbred.
  • the homology regions are separated by a stretch of 122 bp, which contains the sequences targeted by the gRNAs, ensuring that the gRNAs will target only the genome and not the targeting vector itself when they are cotransfected into the cells.
  • the homology regions flank a b-globin HS4-insulated hygromycinresistance gene for selection in PGCs and a loxP site designed to recombine with the downstream loxP sites in the JH-KO selectable marker cassette.
  • PGC line 472-138 contains a previously targeted heavy chain locus in which the JH region (Schusser et al Proc Natl Acad Sci USA. 2013 110:
  • the cell line was derived by breeding a germline chimeric male, which had been injected with JH-KO PGCs, to a wild type hen and culturing cells from the germinal crescent of a Stage 4-8 (Hamburger and Hamilton) EGFP-positive embryo. PGCs were cultured as described [6].
  • PGCs were grown in KO-DMEM (Life Technologies), of which 40% was preconditioned on buffalo rat liver cells (BRL, ATCC), and supplemented with 7.5% fetal bovine serum (Hyclone), 2.5% irradiated chicken serum, IX non-essential amino acids, 2m M glutamine, ImM sodium pyruvate, O.lmM -mercaptoethanol (all from Life Technologies), 4ng/ml recombinant human fibroblast growth factor, 6ng/ml recombinant mouse stem cell factor (both from R&D Systems) and grown on an irradiated feeder layer of BRL cells. The cells were passaged 3 times per week onto fresh feeder layers.
  • the forward primer was KO 6B-F: 5’ -GCTGAACTAGAATGCATCAAGC-3’ (SEQ ID NO: 54) and reverse primer chVH-R33: 5’-ACAAACCTTTGCCGCATCCA-3’ (SEQ ID NO: 55).
  • Cre recombination of inserted loxP site in the IgH locus 3xl0 6
  • Cells from line 1783— 9 carrying the CRISPR-targeted loxP site and JH-KO loxP sites, were transiently transfected with 20pg of a b-actin-Cre expression construct as described above, and cultured for 10 days.
  • the Cre transfection was then repeated to increase the percentage of cells with the excision, and four days later the cells were harvested for PCR analysis of Cre/lox recombination between the two outermost loxP sites.
  • Two PCR assays were performed: both used a 5’ primer in the upstream VH flanking region (chVH-F3aB: 5’-GATG
  • the 3’ primer was located either in the neo gene in the JH-KO (neo-Fl: 5’ -AGCTGTGCTCGACGTTGTC ACT-3’ (SEQ ID NO: 57)) generating a l.6kb amplicon, or in the IgH locus downstream of the selectable markers (chJC-R45: 5’-GCCCAAAATGGCCCCAAAAC-3’ (SEQ ID NO: 58)), generating a 2kb amplicon.
  • EGFP enhanced green fluorescent protein
  • the EGFP gene is part of a selectable marker cassette that was used to knock out the JH gene segment in the JH-KO PGC cell line 472-138 (Fig 10, A).
  • gRNA5 gRNA5
  • GE6 U6-expression vector
  • PGCs were transiently transfected with constructs encoding Cas9 with and without gRNA5.
  • the cell population was analyzed by flow cytometry, and ⁇ 9% of the cells in the Cas9/gRNA5 population had lost EGFP expression compared to the control transfection (Fig 10, B).
  • the modification produced in PGCs must be able to be passed through the germline to the next generation.
  • clonal populations in which every cell carries the desired mutation are preferred.
  • a drug selection strategy was designed in combination with CRISPR/Cas9 to select and grow clones carrying the modification.
  • the region upstream of the single immunoglobulin heavy chain variable region (VH) in the JH-KO cells was targeted for the introduction of a loxP site into the IgH locus.
  • RNAs were designed to direct double-strand cutting of the genome by Cas9 at a site approximately 300bp upstream of the translation initiation site of the VH (Fig 11 , A) and each one was cloned separately into the GE6 vector with Cas9.
  • the Cas9 cut sites are all approximately 50bp from the homology regions in the donor targeting vector, IgH K06B.
  • IgH K06B was constructed with short homology regions of ⁇ lkb flanking a hygromycin selection cassette (Fig 11, A).
  • the chicken IgH locus consists of only short stretches of sequence in the genome database, not organized into contigs, there was sufficient unique sequence available to design PCR primers and amplify these short homology regions.
  • the homology regions were amplified from homozygous JH-KO genomic DNA and are thus isogenic for the allele that contains the JH-KO in the 472-138 cell line.
  • the other allele in these cells is likely to be polymorphic since the bird used for deriving cell line 472-138 was outbred.
  • the 4 gRNAs to VH were separately co-transfected with circular IgH K06B and stable transformants were selected with hygromycin.
  • IgH K06B was used in combination with gRNA/Cas9, the transfections were so efficient that every well for all 4 transfections contained multiple clones of hygromycin-resistant cells.
  • VH region Targeting of the VH region was confirmed independently, taking advantage of the loxP site placed adjacent to the hygromycin gene in the targeted allele.
  • the downstream JH- KO selectable markers are flanked by loxP sites (Boxed) and should be on the same chromosome as the VH loxP site. If the targeting is correct the Cre recombination should excise the intervening DNA and leave behind a single loxP site and the promoterless neo gene (Fig 12, A).
  • Cells of the CRISPR-targeted clone 1783-9 were transiently transfected with a Cre-expression construct two times sequentially (to increase the percentage of cells with the excision) and cells were grown for four days after the second transfection to allow recombination.
  • PCR primers lying outside of the loxP sites amplified the expected size products, whereas in unrecombined cells the primers are about 28kb apart, and no product was observed (Fig. 12, B), indicating that the CRISPR-targeted VH loxP site was in the correct position and orientation.
  • immunoglobulin light chain genes in the chicken occurs prior to colonization of the embryonic bursa of Fabricius. Proc Natl Acad Sci USA (1990) 87:9416-9420.
  • CDRs complementarity determining regions
  • Ig CDR-H3 repertoire Development of the expressed Ig CDR-H3 repertoire is marked by focusing of constraints in length, amino acid use, and charge that are first established in early B cell progenitors. J Immunol (2005) 174:7773-7780.
  • Immunoglobulin analysis tool a novel tool for the analysis of human and mouse heavy and light chain transcripts.

Abstract

L'invention concerne un poulet transgénique ayant un génome comprenant un locus de chaîne lourde d'immunoglobuline (IgH) modifiée. Le locus est dépourvu de la totalité de la région V-D-J de poulet endogène contiguë et contient un segment VH Humain, un groupe D humain, un segment J humain et une pluralité de pseudogènes en amont sur la base de séquences VH humaines. Le locus d'IgH modifié subit une recombinaison V(D)J chez le poulet et le poulet produit des anticorps qui ont une chaîne lourde d'immunoglobuline diversifiée.
EP19770329.1A 2018-03-21 2019-03-05 Poulet transgénique qui produit des anticorps humains Pending EP3768079A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862646319P 2018-03-21 2018-03-21
PCT/US2019/020799 WO2019182751A1 (fr) 2018-03-21 2019-03-05 Poulet transgénique qui produit des anticorps humains

Publications (2)

Publication Number Publication Date
EP3768079A1 true EP3768079A1 (fr) 2021-01-27
EP3768079A4 EP3768079A4 (fr) 2021-12-08

Family

ID=67987909

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19770329.1A Pending EP3768079A4 (fr) 2018-03-21 2019-03-05 Poulet transgénique qui produit des anticorps humains

Country Status (8)

Country Link
US (1) US20210000088A1 (fr)
EP (1) EP3768079A4 (fr)
JP (1) JP2021516954A (fr)
KR (1) KR20200133339A (fr)
CN (1) CN112004411B (fr)
AU (1) AU2019237926A1 (fr)
CA (1) CA3093060A1 (fr)
WO (1) WO2019182751A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3801010A4 (fr) * 2018-06-08 2022-02-23 Crystal Bioscience Inc. Animal transgénique pour la production d'anticorps diversifiés ayant la même chaîne légère i
AU2019350847A1 (en) * 2018-09-26 2021-04-29 Kalamazoo Holdings, Inc. Enzymatic process for production of modified hop products

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040250307A1 (en) * 2000-06-19 2004-12-09 Sujay Singh Transgenic avian species for making human and chimeric antibodies
WO2011019844A1 (fr) * 2009-08-13 2011-02-17 Crystal Bioscience Inc. Animal transgénique pour la production d'anticorps ayant des cdr minimaux

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1151010B1 (fr) * 1999-02-05 2005-10-26 Therapeutic Human Polyclonals, Inc. Anticorps humains polyclonaux d'animaux genetiquement modifies
US20070111259A1 (en) * 1999-10-02 2007-05-17 Medarex, Inc. Human antibodies
CA2634294A1 (fr) * 2000-08-03 2002-02-14 Therapeutic Human Polyclonals, Inc. Production d'anticorps humanises dans des animaux transgeniques
ATE378403T1 (de) * 2000-11-30 2007-11-15 Medarex Inc Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
WO2003081993A2 (fr) * 2002-03-22 2003-10-09 Origen Therapeutics Oiseaux transgeniques producteurs d'anticorps polyclonaux humains
MXPA06000562A (es) * 2003-07-15 2006-03-30 Therapeutic Human Polyclonals Loci de inmunoglobulina humanizada.
WO2009013620A2 (fr) * 2007-06-11 2009-01-29 Erasmus University Medical Center Rotterdam Recombinaison homologue
GB0905023D0 (en) * 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
EP2553100B1 (fr) * 2010-03-31 2017-07-05 Ablexis, LLC Génie génétique sur des animaux non humains pour la production d'anticorps chimériques
JP2012050437A (ja) * 2011-09-12 2012-03-15 Janssen Alzheimer Immunotherapy ベータアミロイドペプチドを認識するヒト化抗体
CN104411717A (zh) * 2012-01-09 2015-03-11 斯克利普斯研究所 具有超长cdr3s的人源化抗体
EP2825652B1 (fr) * 2012-03-15 2018-09-05 Omeros Corporation Composition et procédé de diversification de séquences cible

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040250307A1 (en) * 2000-06-19 2004-12-09 Sujay Singh Transgenic avian species for making human and chimeric antibodies
WO2011019844A1 (fr) * 2009-08-13 2011-02-17 Crystal Bioscience Inc. Animal transgénique pour la production d'anticorps ayant des cdr minimaux

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BENJAMIN SCHUSSER ET AL: "Harnessing Gene Conversion in Chicken B Cells to Create a Human Antibody Sequence Repertoire", PLOS ONE, vol. 8, no. 11, 21 November 2013 (2013-11-21), pages 1 - 15, XP055096053, DOI: 10.1371/journal.pone.0080108 *
KARL ROSNER ET AL: "Third complementarity-determining region of mutated VH immunoglobulin genes contains shorter V, D, J, P, and N components than non-mutated genes", IMMUNOLOGY, vol. 103, 1 January 2001 (2001-01-01), pages 179 - 187, XP055516887 *
KATHRYN H. CHING ET AL: "Chickens with humanized immunoglobulin genes generate antibodies with high affinity and broad epitope coverage to conserved targets", MABS, vol. 10, no. 1, 2 November 2017 (2017-11-02), US, pages 71 - 80, XP055525565, ISSN: 1942-0862, DOI: 10.1080/19420862.2017.1386825 *
PHILIP A. LEIGHTON ET AL: "V(D)J Rearrangement Is Dispensable for Producing CDR-H3 Sequence Diversity in a Gene Converting Species", FRONTIERS IN IMMUNOLOGY, vol. 9, no. 1317, 11 June 2018 (2018-06-11), pages 1 - 14, XP055669112, DOI: 10.3389/fimmu.2018.01317 *
See also references of WO2019182751A1 *
WU LEEYING ET AL: "Fundamental Characteristics of the Immunoglobulin V H Repertoire of Chickens in Comparison with Those of Humans, Mice, and Camelids", vol. 188, no. 1, 1 January 2012 (2012-01-01), US, pages 322 - 333, XP055854741, ISSN: 0022-1767, Retrieved from the Internet <URL:https://www.jimmunol.org/content/jimmunol/188/1/322.full.pdf> DOI: 10.4049/jimmunol.1102466 *

Also Published As

Publication number Publication date
KR20200133339A (ko) 2020-11-27
AU2019237926A1 (en) 2020-09-24
CN112004411B (zh) 2023-05-26
WO2019182751A1 (fr) 2019-09-26
CA3093060A1 (fr) 2019-09-26
EP3768079A4 (fr) 2021-12-08
JP2021516954A (ja) 2021-07-15
CN112004411A (zh) 2020-11-27
US20210000088A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
US10687519B2 (en) Transgenic animal for production of antibodies having minimal CDRs
CN112481300A (zh) 产生抗体的非人哺乳动物
KR20210133234A (ko) 인간화 면역글로불린 유전자좌를 갖는 유전적으로 변형된 비-인간 동물
US20210000088A1 (en) Transgenic chicken that produces human antibodies
US20210227811A1 (en) Transgenic chicken having an endogenous immunoglobulin heavy chain gene in which the igy ch1 coding sequence is functionally deleted
US20210230629A1 (en) Camelization of a human variable domain by gene conversion
US20210227810A1 (en) Production of antibodies by modification of an autonomous heavy chain variable domain by gene conversion
US20210230253A1 (en) Transgenic chicken that makes antibodies with long cdr-h3s stabilized by multiple disulfide bridges and diversified by gene conversion

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200908

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40044085

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20211109

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/00 20060101ALI20211103BHEP

Ipc: C07K 16/46 20060101ALI20211103BHEP

Ipc: A01K 67/027 20060101AFI20211103BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20221103